{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:34:00Z","timestamp":1793129640682,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370163"],"award-info":[{"award-number":["32370163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L2510023"],"award-info":[{"award-number":["L2510023"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232002"],"award-info":[{"award-number":["7232002"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.virs.2026.01.001","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:47:00Z","timestamp":1769014020000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current status of dengue fever epidemics and vaccine development"],"prefix":"10.1016","volume":"41","author":[{"given":"Shiqi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-9465","authenticated-orcid":false,"given":"Ziyang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-1925","authenticated-orcid":false,"given":"Na","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2026.01.001_bib1","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1038\/s41598-017-09199-w","article-title":"Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection","volume":"7","author":"Ali","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virs.2026.01.001_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v17020212","article-title":"Current dengue virus vaccine developments and future directions","volume":"17","author":"Anumanthan","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2026.01.001_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136643","article-title":"Vaccine development using artificial intelligence and machine learning: a review","volume":"282","author":"Asediya","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.virs.2026.01.001_bib4","series-title":"Arming Burkina Faso Scientists with New Skills to Fight Dengue and Other Infectious Diseases","year":"2025"},{"key":"10.1016\/j.virs.2026.01.001_bib5","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2026.01.001_bib7","series-title":"Butantan's Dengue Vaccine Has 79.6% Efficacy, Partial Results from 2-year follow-up Show: Phase 3 Study Initiated in 2016 Included 16,000 Volunteers from Across Brazil and Achieved Primary Objective","year":"2022"},{"key":"10.1016\/j.virs.2026.01.001_bib8","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2026.01.001_bib9","doi-asserted-by":"crossref","first-page":"eaax4144","DOI":"10.1126\/scitranslmed.aax4144","article-title":"Mapping global variation in dengue transmission intensity","volume":"12","author":"Cattarino","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib10","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255671","article-title":"Neighboring mutation-mediated enhancement of dengue virus infectivity and spread","volume":"23","author":"Chen","year":"2022","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.virs.2026.01.001_bib77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.virs.2026.01.001_bib11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-Month-Interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4269\/ajtmh.20-0042","article-title":"Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a Phase-I randomized clinical trial","volume":"103","author":"Durbin","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virs.2026.01.001_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2025.1620572","article-title":"Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow","volume":"8","author":"Elfatimi","year":"2025","journal-title":"Front Artif Intell"},{"key":"10.1016\/j.virs.2026.01.001_bib14","series-title":"Dengue Worldwide Overview","year":"2024"},{"key":"10.1016\/j.virs.2026.01.001_bib15","series-title":"DENGVAXIA","year":"2023"},{"key":"10.1016\/j.virs.2026.01.001_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taad132","article-title":"A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?","volume":"30","author":"Freedman","year":"2023","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib17","author":"General","year":"2019"},{"key":"10.1016\/j.virs.2026.01.001_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib19","first-page":"1407","article-title":"Review of factors influencing transmission risk of dengue fever","volume":"25","author":"Guo","year":"2018","journal-title":"Pract. Prev. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib20","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib24","first-page":"32","article-title":"Increasing dengue burden and severe dengue risk in Bangladesh: an overview","volume":"8","author":"Kayesh","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08347","article-title":"The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus","volume":"4","author":"Kraemer","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.virs.2026.01.001_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm7211a5","article-title":"Notes from the field: first evidence of locally acquired dengue virus infection - maricopa county, Arizona, November 2022","volume":"72","author":"Kretschmer","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.virs.2026.01.001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127216","article-title":"Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue","volume":"57","author":"Kumari","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2026.01.001_bib29","first-page":"925","volume":"24,","author":"Li","year":"2024"},{"key":"10.1016\/j.virs.2026.01.001_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","article-title":"Safety and immunogenicity of an AS03(B)-Adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy U.S. adults: a phase 1\/2 randomized study","volume":"103","author":"Lin","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virs.2026.01.001_bib31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/infdis\/jiaa603","article-title":"Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial","volume":"223","author":"Lin","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib32","first-page":"1","article-title":"Dengue fever in China: new epidemical trend, challenges and strategies for prevention and control","volume":"31","author":"Liu","year":"2020","journal-title":"Chin. J. Vector Biol. Control"},{"key":"10.1016\/j.virs.2026.01.001_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virs.2021.12.001","article-title":"Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan","volume":"37","author":"Ma","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2026.01.001_bib76","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.virs.2026.01.001_bib34","first-page":"385","article-title":"Current situation of the dengue fever in China","volume":"2","author":"Mao","year":"2007","journal-title":"The Current Epidemiological Situation of Dengue Fever in China"},{"key":"10.1016\/j.virs.2026.01.001_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/infdis\/jiv086","article-title":"A promising, single-dose, live attenuated tetravalent dengue vaccine candidate","volume":"212","author":"McArthur","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.virs.2026.01.001_bib78","doi-asserted-by":"crossref","first-page":"104922","DOI":"10.1016\/j.ebiom.2023.104922","article-title":"Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study","volume":"99","author":"Miauton","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virs.2026.01.001_bib37","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300098R","article-title":"Higher-temperature-adapted dengue virus serotype 2 strain exhibits enhanced virulence in AG129 mouse model","volume":"37","author":"Modak","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.virs.2026.01.001_bib38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib39","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/S0140-6736(19)32689-3","article-title":"The dengue epidemic and climate change in Nepal","volume":"394","author":"Pandey","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2026.01.001_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.meegid.2018.04.032","article-title":"Understanding dengue virus evolution to support epidemic surveillance and counter-measure development","volume":"62","author":"Pollett","year":"2018","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.virs.2026.01.001_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib42","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2026.01.001_bib43","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2026.01.001_bib44","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib46","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1186\/s12889-022-13720-w","article-title":"Does COVID-19 lockdowns have impacted on global dengue burden? A special focus to India","volume":"22","author":"Sharma","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.virs.2026.01.001_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib48","article-title":"Understanding the unprecedented 2023 dengue outbreak in Bangladesh: a data-driven analysis","volume":"12","author":"Subarna","year":"2024","journal-title":"IJID Reg"},{"key":"10.1016\/j.virs.2026.01.001_bib49","series-title":"Takeda Announces Voluntary Withdrawal of U.S. Biologics License Application (BLA) for Dengue Vaccine Candidate TAK-003","year":"2023"},{"key":"10.1016\/j.virs.2026.01.001_bib50","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virs.2026.01.001_bib51","first-page":"1","article-title":"Epidemiology of dengue reported in the World Health Organization's Western Pacific Region, 2013-2019","volume":"14","author":"Togami","year":"2023","journal-title":"West. Pac. Surveill. Response J."},{"key":"10.1016\/j.virs.2026.01.001_bib52","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virs.2026.01.001_bib53","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virs.2026.01.001_bib80","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S1473-3099(24)00609-1","article-title":"Global upsurge in dengue in 2024","volume":"24","author":"Venkatesan","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.virs.2026.01.001_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(23)00520-0","article-title":"Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial","volume":"24","author":"Walsh","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD\u2122 vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.virs.2026.01.001_bib57","series-title":"Dengue Vaccine: WHO Position Paper, September 2018 \u2013 Recommendations","year":"2019"},{"key":"10.1016\/j.virs.2026.01.001_bib58","series-title":"Ten Threats to Global Health in 2019","year":"2019"},{"key":"10.1016\/j.virs.2026.01.001_bib59","series-title":"Dengue - Global Situation","year":"2023"},{"key":"10.1016\/j.virs.2026.01.001_bib60","series-title":"Dengue and Severe Dengue","year":"2023"},{"key":"10.1016\/j.virs.2026.01.001_bib61","series-title":"Dengue in the WHO African Region: Situation Report 01: 19 December 2023","year":"2023"},{"key":"10.1016\/j.virs.2026.01.001_bib62","series-title":"Vaccines and Immunization: Dengue [EB\/OL]","year":"2024"},{"key":"10.1016\/j.virs.2026.01.001_bib63","series-title":"Dengue","year":"2025"},{"key":"10.1016\/j.virs.2026.01.001_bib64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(23)00565-0","article-title":"The dengue-in-dhaka initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh","volume":"24","author":"Wilder-Smith","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib65","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2214-109X(23)00590-9","article-title":"TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden","volume":"12","author":"Wilder-Smith","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.virs.2026.01.001_bib66","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4269\/ajtmh.13-0600","article-title":"Lineage II of Southeast Asian\/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon","volume":"91","author":"Williams","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virs.2026.01.001_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.virs.2026.01.001_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2245","article-title":"Dengue fever and dengue virus in the People'S Republic of China","volume":"32","author":"Wu","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.virs.2026.01.001_bib69","first-page":"167","article-title":"The research progress of dengue fever","volume":"17","author":"Yuan","year":"2005","journal-title":"Shanghai Prevent. Med."},{"key":"10.1016\/j.virs.2026.01.001_bib70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2019.06.015","article-title":"Epidemiological dynamics of dengue fever in mainland China, 2014-2018","volume":"86","author":"Yue","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.virs.2026.01.001_bib71","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.3390\/ijerph19073910","article-title":"Dengue fever in mainland China, 2005-2020: a descriptive analysis of dengue cases and aedes data","volume":"19","author":"Yue","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.virs.2026.01.001_bib72","first-page":"341","article-title":"Spatio-Temporal Distribution and Environmental Factors of Dengue Fever in China, 2020\u20142022","volume":"13","author":"Yue","year":"2023","journal-title":"J. Environ. Hygiene"},{"key":"10.1016\/j.virs.2026.01.001_bib73","first-page":"761","article-title":"Epidemiological Characteristics of Dengue Fever in Chinese mainland,2005-2020","volume":"34","author":"Yue","year":"2023","journal-title":"Chin J Vector Biol Control"},{"key":"10.1016\/j.virs.2026.01.001_bib74","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1186\/s12889-025-24151-8","article-title":"Dengue situation in Chinese mainland, 2023","volume":"25","author":"Yue","year":"2025","journal-title":"BMC Public Health"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X26000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X26000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:33:41Z","timestamp":1776195221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X26000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1995820X26000076"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2026.01.001","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of dengue fever epidemics and vaccine development","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2026.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}